RRM2 and neoplasm: This study identified three potential tumor drivers of advanced prostate cancer, including CDC20, DTL, and RRM2, through integrative bioinformatic screening that considered gene dependency using CRISPRi/RNAi database, clinical relevance, and experimental validation with CRISPR-Cas13-mediated gene ablation.